Equity · Healthcare
NUVB
NYSENuvation Bio (NUVB)
The line runs 6.77 USD on 24 August through 5.84 USD on 18 September, on a scale from 5.5 to 7.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 2.1B USD
- Revenue, year to Dec 2025
- 62.9M USD
- EPS, diluted, year to Dec 2025
- −0.60 USD
- 52-week range
- 3 USD – 9.53 USD
- Avg volume
- 391.3K
as of Sep 18, 2026
Have Nuvation Bio (NUVB) insiders bought or sold shares recently?
NUVB's newest Form 4 filing is dated 19 August 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Aug 2026 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Sell | 100,000 | 709K USD |
| 23 Jun 2026 | Markel StacyCHIEF PEOPLE OFFICER | Sell | 125,000 | 753K USD |
| 23 Jun 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Sell | 63,000 | 379K USD |
| 23 Jun 2026 | Sauvage PhilippeChief Financial Officer | Sell | 47,668 | 286K USD |
| 09 Jun 2026 | Mashal RobertDirector | Buy | 25,000 | 118K USD |
| 17 Apr 2026 | Liu DongfangCHIEF MEDICAL OFFICER | Sell | 50,000 | 251K USD |
| 17 Apr 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Sell | 36,750 | 184K USD |
| 06 Apr 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Sell | 200,000 | 904K USD |
| 01 Dec 2025 | Liu DongfangCHIEF MEDICAL OFFICER | Sell | 150,000 | 1.2M USD |
| 26 Nov 2025 | Liu DongfangCHIEF MEDICAL OFFICER | Sell | 10,000 | 80K USD |
| 25 Nov 2025 | Liu DongfangCHIEF MEDICAL OFFICER | Sell | 10,000 | 75K USD |
| 20 Nov 2025 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Sell | 369,051 | 2.7M USD |
| Bought | 1 open-market purchase | 25,000 | $118K | |
| Sold | 16 open-market sales | 1,511,469 | $9.68M |
Showing the 12 most recent of 17 open-market trades in this window. The figures above count all of them.
18 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Aug 2026 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Option exercise | 100,000 | 187K USD |
| 15 Jul 2026 | Sauvage PhilippeChief Financial Officer | Option exercise | 40,000 | 87K USD |
| 23 Jun 2026 | Markel StacyCHIEF PEOPLE OFFICER | Option exercise | 125,000 | 229K USD |
| 23 Jun 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Option exercise | 63,000 | 185K USD |
| 23 Jun 2026 | Sauvage PhilippeChief Financial Officer | Option exercise | 47,668 | 103K USD |
| 17 Apr 2026 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise | 50,000 | 97K USD |
| 17 Apr 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Option exercise | 36,750 | 108K USD |
| 06 Apr 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Option exercise | 200,000 | 381K USD |
| 27 Feb 2026 | Makunje MosesSEE REMARKS | Award | 50,761 | |
| 01 Dec 2025 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise | 150,000 | 440K USD |
| 26 Nov 2025 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise | 10,000 | 36K USD |
| 25 Nov 2025 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise | 10,000 | 36K USD |
Showing the 12 most recent of 18 compensation filings in this window. The figures above count all of them.
Which funds hold Nuvation Bio (NUVB)?
11 of the 45 institutional funds we track reported a Nuvation Bio position for the quarter ended 30 Sep 2026 — a combined 82.0M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Added | 3,300,303 | 18.5M USD | +164.4% |
| AQR Capital Management | Held (±25%) | 2,508,296 | 14.0M USD | +6.4% |
| Citadel Advisors | Held (±25%) | 2,371,009 | 13.3M USD | +19.2% |
| Duquesne Family Office | Trimmed | 2,269,900 | 12.7M USD | −50.0% |
| Renaissance Technologies | Held (±25%) | 1,319,695 | 7.4M USD | −2.0% |
| D. E. Shaw & Co. | Held (±25%) | 903,310 | 5.1M USD | −20.8% |
| Millennium Management | Added | 700,196 | 3.9M USD | +87.8% |
| Man Group | Added | 695,454 | 3.9M USD | +69.4% |
| Marshall Wace | Added | 283,536 | 1.6M USD | +240.0% |
| Tudor Investment Corp | New position | 267,032 | 1.5M USD |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
What has been filed or recorded for Nuvation Bio (NUVB)?
The filings we hold for Nuvation Bio, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 23 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,087,115 shares | 5.1M USD notional · 0.308% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 200 shares | 890 USD notional · <0.001% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 11,097 shares | 53K USD notional · 0.003% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 44,606 shares | 209K USD notional · 0.013% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.12 USD | Revenue $45M |
| 30 Sep 2026 | Financials | Total assets | 778.4M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 228.0M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.18 USD | Revenue $32M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.01 USD | Revenue $83M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.60 USD | Revenue $63M |
| 31 Dec 2025 | Financials | Revenue | 62.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −204.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.60 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.16 USD | Revenue $13M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.17 USD | Revenue $5M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.16 USD | Revenue $3M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.11 USD | Revenue $8M |
What do people ask about Nuvation Bio (NUVB)?
What did Nuvation Bio shares close at?5.84
Nuvation Bio closed at 5.84 USD on 18 Sep 2026, down 3.95% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Nuvation Bio’s market cap?2.1B
Nuvation Bio is worth 2.1B USD by market value as of 18 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Nuvation Bio’s revenue?62.9M
Nuvation Bio reported revenue of 62.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Nuvation Bio insiders bought or sold shares recently?
No Nuvation Bio insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 19 Aug 2026 (SEC Form 4). See Insiders
Which funds own Nuvation Bio?11 of 45
11 of the 45 funds we track reported a Nuvation Bio position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, AQR Capital Management and Citadel Advisors. See Funds
When did Nuvation Bio last report earnings?−0.12
Nuvation Bio last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.12 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words